Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

The role of selegiline in the treatment of negative symptoms associated with schizophrenia.

Fohey KD, Hieber R, Nelson LA.

Ann Pharmacother. 2007 May;41(5):851-6. Epub 2007 Apr 3. Review.

PMID:
17405823
2.

Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.

Amiri A, Noorbala AA, Nejatisafa AA, Ghoreishi A, Derakhshan MK, Khodaie-Ardakani MR, Hajiazim M, Raznahan M, Akhondzadeh S.

Hum Psychopharmacol. 2008 Mar;23(2):79-86.

PMID:
17972359
3.

Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review.

Saavedra-Velez C, Yusim A, Anbarasan D, Lindenmayer JP.

J Clin Psychiatry. 2009 Jan;70(1):104-12. Epub 2008 Nov 18. Review.

PMID:
19026265
4.

Deprenyl augmentation for treating negative symptoms of schizophrenia: a double-blind, controlled study.

Jungerman T, Rabinowitz D, Klein E.

J Clin Psychopharmacol. 1999 Dec;19(6):522-5.

PMID:
10587287
5.
6.

Selegiline augmentation of antipsychotics for the treatment of negative symptoms in schizophrenia.

Gupta S, Droney T, Kyser A, Keller P.

Compr Psychiatry. 1999 Mar-Apr;40(2):148-50.

PMID:
10080262
7.
8.

Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis.

Sepehry AA, Potvin S, Elie R, Stip E.

J Clin Psychiatry. 2007 Apr;68(4):604-10.

PMID:
17474817
9.

Adjunct mirtazapine for negative symptoms of schizophrenia.

Phan SV, Kreys TJ.

Pharmacotherapy. 2011 Oct;31(10):1017-30. doi: 10.1592/phco.31.10.1017. Review.

PMID:
21950644
10.

Allopurinol as adjuvant therapy in poorly responsive or treatment refractory schizophrenia.

Buie LW, Oertel MD, Cala SO.

Ann Pharmacother. 2006 Dec;40(12):2200-4. Epub 2006 Nov 21. Review.

PMID:
17119103
11.

Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.

Fernandez HH, Chen JJ.

Clin Neuropharmacol. 2007 May-Jun;30(3):150-68. Review.

PMID:
17545750
12.

Role of mirtazapine in the treatment of antipsychotic-induced akathisia.

Hieber R, Dellenbaugh T, Nelson LA.

Ann Pharmacother. 2008 Jun;42(6):841-6. doi: 10.1345/aph.1K672. Epub 2008 May 6.

PMID:
18460588
13.

Modafinil augmentation for residual symptoms of fatigue in patients with a partial response to antidepressants.

Lam JY, Freeman MK, Cates ME.

Ann Pharmacother. 2007 Jun;41(6):1005-12. Epub 2007 May 22. Review.

PMID:
17519297
14.

Use of histamine2-antagonists for the treatment of verruca vulgaris.

Fit KE, Williams PC.

Ann Pharmacother. 2007 Jul;41(7):1222-6. Epub 2007 May 29. Review.

PMID:
17535844
15.

Selegiline in treatment of behavioral and cognitive symptoms of Alzheimer disease.

Tolbert SR, Fuller MA.

Ann Pharmacother. 1996 Oct;30(10):1122-9. Review.

PMID:
8998375
16.

Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.

Fowler JA, Bettinger TL, Argo TR.

Clin Ther. 2008 Feb;30(2):231-48. doi: 10.1016/j.clinthera.2008.02.011. Review.

PMID:
18343262
17.

Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men.

Gales BJ, Gales MA.

Ann Pharmacother. 2008 Jan;42(1):111-5. Epub 2007 Dec 19. Review.

PMID:
18094344
18.

Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of 'off' episodes in patients with Parkinson's disease.

Lew MF, Pahwa R, Leehey M, Bertoni J, Kricorian G; Zydis Selegiline Study Group.

Curr Med Res Opin. 2007 Apr;23(4):741-50.

PMID:
17407630
19.

Oral cholinesterase inhibitor add-on therapy for cognitive enhancement in schizophrenia: a quantitative systematic review, Part I.

Chouinard S, Sepehry AA, Stip E.

Clin Neuropharmacol. 2007 May-Jun;30(3):169-82. Review.

PMID:
17545751

Supplemental Content

Support Center